Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

21.69USD
13 Sep 2019
Change (% chg)

$-0.55 (-2.47%)
Prev Close
$22.24
Open
$22.47
Day's High
$22.90
Day's Low
$21.66
Volume
1,960,407
Avg. Vol
2,452,789
52-wk High
$39.59
52-wk Low
$16.64

Select another date:

Fri, Aug 30 2019

U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta

The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly and Co's lung cancer drug Alimta.

U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta

The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly and Co's lung cancer drug Alimta.

U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta

Aug 29 The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly and Co's lung cancer drug Alimta.

Denmark's Novo Nordisk files lawsuit against Mylan over patent

COPENHAGEN, Aug 22 Novo Nordisk said on Thursday it has filed litigation in a Delaware district court against Mylan aimed at blocking its attempt to market a generic version of the Danish insulin maker's drug Victoza.

Teva to launch generic version of EpiPen for young children

Teva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan's EpiPen for young children will be available in most retail pharmacies at a price of $300 for a 2-pack.

Teva to launch generic version of EpiPen for young children

Aug 20 Teva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan's EpiPen for young children will be available in most retail pharmacies at a price of $300 for a 2-pack.

UPDATE 1-U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis

Aug 14 The U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL, the not-for-profit said on Wednesday.

U.S. lawmakers push Mylan, Teva over drug pricing probe

WASHINGTON The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

UPDATE 3-U.S. lawmakers push Mylan, Teva over drug pricing probe

WASHINGTON, Aug 14 The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

U.S. lawmakers push Mylan, Teva over drug pricing probe -statement

WASHINGTON, Aug 14 The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Select another date: